Upadacitinib Shows 1-Year Benefit in Pediatric IBD

By News Health
37 minutes Ago

(MedPage Today) — LAS VEGAS — Upadacitinib (Rinvoq) showed durable clinical benefit at 1 year among children and adolescents with inflammatory bowel disease (IBD), a single-center study found.
In the retrospective study of 48 patients with…

Source link : https://www.medpagetoday.com/meetingcoverage/ccc/119563

Author :

Publish date : 2026-01-23 21:54:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Neonatal Mortality Increased With Number of Mom's Chronic Conditions

Sensitization to Pet Allergens Tied to Asthma Symptoms

PCP Numbers See a Decline for New Patient Visits

Congress Pressed on NIH Neurology Leadership Change

Prior Biologic Use Tied to JAK Inhibitor Benefit in Ulcerative Colitis

Aortic Emergencies More Likely After Cold Temps